StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)

Close on Nov 17, 2026Market cap $264.95MP/E –Yield –

Prelude Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Prelude Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$33.26M. For fiscal 2025 it was -$56.30M. The highest annual figure on record is -$25.67M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$56.30M–
FY2024Dec 31, 2024-$102.89M–
FY2023Dec 31, 2023-$107.06M–
FY2022Dec 31, 2022-$83.73M–
FY2021Dec 31, 2021-$83.53M–
FY2020Dec 31, 2020-$46.18M–
FY2019Dec 31, 2019-$25.67M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.57M–
Q1 FY2026Mar 31, 2026-$21.69M–
Q4 FY2025Dec 31, 2025$23.12M–
Q3 FY2025Sep 30, 2025-$19.12M–
Q2 FY2025Jun 30, 2025-$26.08M–
Q1 FY2025Mar 31, 2025-$34.23M–
Q4 FY2024Dec 31, 2024-$20.74M–
Q3 FY2024Sep 30, 2024-$27.30M–
Q2 FY2024Jun 30, 2024-$23.06M–
Q1 FY2024Mar 31, 2024-$31.79M–
Q4 FY2023Dec 31, 2023-$23.58M–
Q3 FY2023Sep 30, 2023-$25.68M–
Q2 FY2023Jun 30, 2023-$27.67M–
Q1 FY2023Mar 31, 2023-$30.13M–
Q4 FY2022Dec 31, 2022-$22.93M–
Q3 FY2022Sep 30, 2022-$20.44M–
Q2 FY2022Jun 30, 2022-$18.47M–
Q1 FY2022Mar 31, 2022-$21.90M–
Q4 FY2021Dec 31, 2021-$25.70M–
Q3 FY2021Sep 30, 2021-$21.77M–
Q2 FY2021Jun 30, 2021-$19.91M–
Q1 FY2021Mar 31, 2021-$16.14M–
Q4 FY2020Dec 31, 2020-$14.85M–
Q3 FY2020Sep 30, 2020-$12.51M–
Q2 FY2020Jun 30, 2020-$8.90M–
Q1 FY2020Mar 31, 2020-$9.92M–
Q4 FY2019Dec 31, 2019-$8.47M–

More Prelude Therapeutics figures

See a number that looks wrong?